OBJECTIVES: To estimate the incremental costs of visual inspection with acetic acid (VIA) and cryotherapy at cervical cancer screening facilities in Ghana; to explore determinants of costs through modelling; and to estimate national scale-up and annual programme costs. METHODS: Resource-use data were collected at four out of six active VIA screening centres, and unit costs were ascertained to estimate the costs per woman of VIA and cryotherapy. Modelling and sensitivity analysis were used to explore the influence of observed differences between screening facilities on estimated costs and to calculate national costs. RESULTS: Incremental economic costs per woman screened with VIA ranged from 4.93 US$ to 14.75 US$, and costs of cryotherapy were between 47.26 US$ and 84.48 US$ at surveyed facilities. Under base case assumptions, our model estimated the costs of VIA to be 6.12 US$ per woman and those of cryotherapy to be 27.96 US$. Sensitivity analysis showed that the number of women screened per provider and treated per facility was the most important determinants of costs. National annual programme costs were estimated to be between 0.6 and 4.0 million US$ depending on assumed coverage and adopted screening strategy. CONCLUSION: When choosing between different cervical cancer prevention strategies, the feasibility of increasing uptake to achieve economies of scale should be a major concern.
References
Health Econ. 2004 Jan;13(1):21-35
[PMID: 14724891]
BMC Health Serv Res. 2008 Jan 31;8:26
[PMID: 18234117]
J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83
[PMID: 12359856]
Int J Cancer. 2007 Nov 15;121(10):2218-24
[PMID: 17657715]
Vaccine. 2009 May 29;27 Suppl 1:A46-53
[PMID: 19480962]
N Engl J Med. 2005 Nov 17;353(20):2158-68
[PMID: 16291985]
Reprod Health Matters. 2008 Nov;16(32):67-77
[PMID: 19027624]
